Genomic Health, Inc.
GENOMIC HEALTH INC (Form: 8-K, Received: 06/11/2018 16:07:31)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 


 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  June 6, 2018

 

GENOMIC HEALTH, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

 

000-51541

 

77-0552594

(State or other jurisdiction

 

(Commission

 

(IRS Employer

of incorporation)

 

File Number)

 

Identification No.)

 

301 Penobscot Drive, Redwood City, California

 

94063

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code:  (650) 556-9300

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of Regulation S-K of the Securities Act (17 CFR 230.405) or Rule 12b-2 of the Exchange Act (17 CFR 240.12b-2):

 

Emerging growth company  o

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

 

 

 



 

Item 5.07                Submission of Matters to a Vote of Security Holders.

 

The following actions were taken at the Annual Meeting of Stockholders of Genomic Health, Inc. (the “Company”), held on June 6, 2018:

 

1.                                      The following Directors were elected to serve until the 2019 Annual Meeting or until their successors are duly elected and qualified:

 

 

 

For

 

Withheld

 

Broker
Non-Votes

 

 

 

 

 

 

 

 

 

Kimberly J. Popovits

 

28,760,929

 

974,751

 

3,985,134

 

 

 

 

 

 

 

 

 

Felix J. Baker, Ph.D.

 

27,186,166

 

2,549,514

 

3,985,134

 

 

 

 

 

 

 

 

 

Julian C. Baker

 

27,802,849

 

1,932,831

 

3,985,134

 

 

 

 

 

 

 

 

 

Fred E. Cohen, M.D., D.Phil.

 

19,760,392

 

9,975,288

 

3,985,134

 

 

 

 

 

 

 

 

 

Henry J. Fuchs, M.D.

 

27,391,414

 

2,344,266

 

3,985,134

 

 

 

 

 

 

 

 

 

Ginger L. Graham

 

29,073,537

 

662,143

 

3,985,134

 

 

 

 

 

 

 

 

 

Geoffrey M. Parker

 

29,592,954

 

142,726

 

3,985,134

 

 

2.                                       An Amendment to the Amended and Restated Genomic Health, Inc. 2005 Stock Incentive Plan was approved.

 

For

 

Against

 

Abstain

 

Broker
Non-Votes

 

21,211,349

 

8,501,751

 

22,580

 

3,985,134

 

 

3.                                       The compensation of the Company’s named executive officers was approved, on a non-binding advisory basis.

 

For

 

Against

 

Abstain

 

Broker
Non-Votes

 

29,419,982

 

284,235

 

31,463

 

3,985,134

 

 

4.                                       The ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the 2018 fiscal year was approved.

 

For

 

Against

 

Abstain

 

 

 

33,650,904

 

47,588

 

22,322

 

 

 

 

5.                                       The stockholder proposal concerning proxy access was not approved.

 

For

 

Against

 

Abstain

 

Broker
Non-Votes

 

13,230,802

 

16,467,929

 

36,949

 

3,985,134

 

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated:  June 11, 2018

 

 

GENOMIC HEALTH, INC.

 

 

 

 

 

 

 

By

/s/ Jason W. Radford

 

Name:

Jason W. Radford

 

Title:

Chief Legal Officer

 

3